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Abstract

Objective: To estimate the annual incidence of vulvodynia-like symptoms and evaluate triggers of vulvar pain
in a sample of U.S. women.
Methods: After a 1-year interval, women who previously participated in a national vulvodynia prevalence study
were recontacted and administered a telephone questionnaire that assessed self-reported vulvodynia-like symptoms and triggers of symptoms.
Results: From the original cohort of 425 women, 285 (67%) participated in this follow-up study. Symptoms consistent with vulvodynia occurring within 1 year of initial contact were reported by 4.7% of previously asymptomatic women. Nearly 50% of the original patients again reported a history of vulvodynia-like symptoms,
with 68.6% of these as persistent over the past year. Of significance, pain or discomfort with first-time tampon
use was 2.15 times more likely (95% CI 1.0-4.62) in symptomatic women. These women were also 2.4 times
more likely (95% CI 1.29-4.53) to use a combination of tampons and pads for sanitary protection rather than
one method alone.
Conclusions: Over the course of 1 year, as many as 1 in 20 women may experience new-onset chronic genital
pain. Despite a higher likelihood of having discomfort or pain with first tampon use, symptomatic women did
not exhibit a preference for sanitary napkins. This indicates that lack of tampon use because of pain may not be
an effective screening criterion for vulvodynia. We recommend additional studies with symptomatic and diagnosed women to explore in more detail the issues surrounding tampon use history and chronic genital pain.
Introduction

V

or localized vulvar pain
syndrome of uncertain etiology characterized by intermittent or constant discomfort or pain, with burning, stinging, irritation, or rawness lasting for 6 months of longer,
which clinically is a diagnosis of exclusion.1 Factors complicating diagnosis include vague symptoms,2 absence of vulvar pathological conditions,3 clinicians unfamiliar with the
condition,4 and lack of a confirmatory diagnostic test. AlULVODYNIA IS A GENERALIZED

though vulvodynia was described in the literature in the late
1800s,5 many questions about its epidemiology and risk factors remain.
The lifetime prevalence of vulvodynia is approximately
9%–16% in the U.S. female population.6–8 Studies evaluating
vulvodynia have been limited by the lack of incidence data
that would further characterize this gynecological condition,
which affects up to 14 million women in the United States
during their lifetime.7
This follow-up national telephone survey ascertained the
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number of women who reported new vulvodynia-like symptoms and those who denied these symptoms 1 year after initial contact by this study team. As well, current literature
suggests that women experiencing pain with first tampon
use have an increased risk of later developing vulvodynia
compared with women not reporting pain with initial tampon use.4,7,9 To explore this issue, tampon use history in this
cohort also was collected.
Materials and Methods
Approval for this study was obtained from both the University of Medicine and Dentistry of New Jersey (UMDNJ)
Institutional Review Board and Independent Research Consulting. This is a follow-up study to the 2003 national telephone survey by Arnold et al.,6 which identified 100 women
with self-reported symptoms suggestive of vulvodynia
(cases) and 325 asymptomatic women (controls). For the purpose of the original study, a listed sample of U.S. phone numbers was purchased from Survey Sampling, Inc. (Fairfield,
CT), and used to identify participants. Controls were
matched to cases on 5-year age intervals and time zone, with
the four major U.S. time zones represented. Women were excluded if they reported an active gynecological infection or
a positive history of conditions known to mimic and complicate the diagnosis of vulvodynia.6,10 Additional details
about subject selection, calling disposition, and survey administration have been described previously.6
In this study, up to four phone calls were made on different weekdays and times in an attempt to recontact 424 of
the 425 women who participated in the original survey 1year earlier; one phone number was not recorded in the initial study, and this subject was lost to follow-up. Participants
answered a 19-item survey that lasted an average of 10
minutes. They were rescreened for symptoms of vulvodynia
using the same criteria adopted in the initial study.6 In accordance with International Society for the Study of Vulvovaginal Disease (ISSVD) guidelines, vulvodynia symptoms
were defined as unexplained intermittent or constant discomfort or pain, with burning, stinging, irritation, or rawness lasting for 6 months or longer.1 The Henne Group (San
Francisco, CA), the research consulting firm that conducted
the initial study, implemented the follow-up questionnaire
using the Computer Aided Telephone Interviewing (CATI)
system as a means of minimizing interviewer bias. Participants’ identification as cases or controls was known to the
interviewers, as it was noted in the dataset in response to the
question assessing symptom history.
Contact, cooperation, and response rates were calculated
using the American Association for Public Opinion Research
(AAPOR) definitions.11 Chi-square, Fischer’s exact test, and
t tests were used to examine differences between populations as appropriate. Odds ratios (OR) and 95% confidence
intervals (CIs) were used to characterize associations between vulvodynia-like symptoms and tampon use variables.
SPSS 10.1 and SAS 9.1 (Cary, NC) were used for analysis,
with statistical significance set at p  0.05.
Results
Of the 425 women from the initial national prevalence survey, 318 (75%) were successfully recontacted (Table 1).
Among the 107 remaining women, 88 (or 21% of the origi-
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nal sample) had either moved or disconnected their number,
thus preventing the possibility of recontact. The study obtained a cooperation rate of 89.6% and a response rate of
67.2%, resulting in 285 participants. Characteristics of responders and nonresponders were examined using data
gathered in the original survey (Table 2). Significant differences were found with respect to age, marital status, level of
education, and race. Nonresponders were typically younger
than responders, with more than half 45 years of age
(54.17% vs. 35.09%). They also tended to be single or divorced/separated (34.79% vs. 17.09%) and of a race other
than Caucasian or black (14.29% vs. 6.67%). Whereas more
than one third of each population had at least a college degree, responders were more likely to have a graduate degree
(16.84% vs. 5.76%). Although there were no significant differences in employment status, a higher proportion of responders were retired (24.82% vs. 13.77%). With respect to
health status, there were no significant differences in self-reported quality of life, stress levels, overall health, and history of depression.
The follow-up population in this study comprised 213
original controls and 72 original cases (Fig. 1). When subjects
were reassessed for history of vulvodynia-like symptoms, 17
of the 213 controls reported ever experiencing symptoms.
Ten of these women stated symptoms occurred since the last
telephone contact, yielding an incidence of 4.7%. Seven controls reported experiencing vulvodynia-like symptoms more
than 1 year ago and, therefore, were not included in the incidence calculation.
It was expected that at follow-up, the 72 original cases
would again report a positive history of vulvodynia-like
symptoms; however, only 35 reconfirmed their case status
(Fig. 1), 24 (68.6%) of whom stated the most recent symptoms occurred within the past year. Surprisingly, 36 original
cases denied ever having symptoms, and 1 refused to answer the question. As no questions were asked to determine
if this inconsistency in answers was due to a misunderstanding of the question or inaccurate self-reporting, data
from these 37 women were not included in the follow-up
analysis in either the symptomatic or asymptomatic groups.
Thus, the follow-up analysis divided women into an asymptomatic group (n  196) confined to subjects who denied
symptoms in both studies and a symptomatic group (n  52)
TABLE 1. CALLING DISPOSITION AND CODING FOR
CALCULATING CONTACT, COOPERATION, AND RESPONSE
RATES OF 425 WOMEN IN FOLLOW-UP STUDY
Calling disposition
Complete
Partial
Subject died or unavailable
Unable to participate (physical,
mental, miscellaneous reasons)
Disconnected number
Respondent no at residence
Refusal––Do not call
Phone number not recorded in
original survey

No. of records

Codea

285
2
18
3

I
P
NC
O

58
30
28
1

NC
NC
R
NC

aContact reported as: I  complete interview; P  partial interview; NC  noncontact; R  refusal and breakoff; O  other.
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TABLE 2.

CHARACTERISTICS

Characteristic
Age range, No. (%)
18–24 years
25–34 years
35–44 years
45–54 years
55–64 years
65–80 years
Employment status, No.b (%)
Employed (full or part-time)
Student/homemaker
Unemployed
Retired
Marital status, No.c (%)
Single, never married
Divorced/separated
Widowed
Married/marriagelike relationship
Education, No.d (%)
High school or less
Some college/associate’s degree
College degree
Graduate degree
Race, No. (%)
White
Black
Other
Overall health,e mean  SD
Quality of life,f mean  S.D.
Level of stress,g mean  S.D.
Depression, No. (%)

OF

RESPONDERS

AND

1287
NONRESPONDERS

Responders
(n  285)

IN

FOLLOW-UP SURVEYa

Nonresponders
(n  140)

p value
0.0001

7
36
57
66
53
66

(2.46%)
(12.63%)
(20%)
(23.16%)
(18.6%)
(23.16%)

18
38
24
22
19
19

(12.86%)
(27.14%)
(17.14%)
(15.71%)
(13.57%)
(13.57%)

158
36
12
68

(57.66%)
(13.14%)
(4.38%)
(24.82%)

90
20
9
19

(65.22%)
(14.49%)
(6.52%)
(13.77%)

27
22
27
209

(9.47%)
(7.72%)
(9.47%)
(73.33%)

27
21
6
84

(19.57%)
(15.22%)
(4.35%)
(60.87%)

77
88
72
48

(27.02%)
(30.88%)
(25.26%)
(16.84%)

49
43
39
8

(35.25%)
(30.94%)
(28.06%)
(5.76%)

0.068

0.0005

0.0112

0.0107
248 (87.02%)
18 (6.32%)
19 (6.67%)
2.29  1.01
8.34  4.99
6.06  7.75
73 (25.61%)

106 (75.71%)
14 (10%)
20 (14.29%)
2.36  1.06
9.68  12.29
5.70  2.539
45 (32.14%)

aBased

on data provided in the original survey (Arnold et al.6).
 11 responders and n  2 nonresponders answered “other.”
cn  2 refused to provide relationship status.
dn  1 nonresponder answered “other.”
eSelf-reported on a 1–5 scale, where 1  excellent and 5  poor.
fSelf-reported on a 1–10 scale, where 1  worst possible and 10  best possible quality of life.
gSelf-reported on a 1–10 scale, where 1  least possible and 10  most possible amount of stress.
bn

comprised of the 35 reconfirmed cases plus the 17 original
controls who reported vulvodynia-like symptoms at followup.
Symptomatic and asymptomatic women were similar in
age, menopausal status, and racial distribution (Table 3). Although the symptomatic group reported significantly higher
stress levels, there were no differences noted regarding quality of life and assessment of overall health. When questioned
about chronic pain or discomfort with tampon insertion,
speculum insertion, intercourse, and exercise, a significantly
higher proportion of symptomatic women reported situational pain in all four circumstances (Table 4). Notably, half
of the symptomatic group experienced dyspareunia, and
slightly more than 25% experienced pain with tampon and
speculum insertion, compared with 5% of their asymptomatic counterparts.
Several questions were designed to investigate relationships between vulvodynia-like symptoms and menstrual
history, specifically tampon use. When queried about preferred method of sanitary protection, symptomatic women

were 2.4 times as likely to report using a combination of pads
and tampons as opposed to one method alone. Of the subgroup not using tampons, symptomatic women were nearly
twice as likely as asymptomatic women to report using only
sanitary pads during menstruation because of discomfort
with tampon use (OR 1.92, 95% CI 0.57-6.41), although this
finding was not statistically significant (Table 5). Similarly,
of those who had tried tampons, symptomatic women were
twice as likely to report a history of discomfort or pain with
first-time use (OR 2.15, 95% CI 1.0-4.62). A small but nonsignificant portion of these women (6.1%) found their first
tampon experience so painful that they never used them
again.
Discussion and Conclusions
This is the first study of which we are aware that followed
a nationally selected group of women in a nonclinic setting
across time, assessing the incidence of vulvodynia-like
symptoms. This national telephone survey yielded a 4.7% in-
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285
Follow-up subjects

72
Cases
(Previously reported VLS)

213
Controls
(Previously denied VLS)

196
Denied VLS

17
Reported VLS

10
Reported VLS
within past year

FIG. 1.

35
Reported VLS

36
Denied VLS

1
Refused to
answer vulvar
pain question

7
Reported VLS
occurring > 1
year ago

Characterization of vulvodynia-like symptoms (VLS) among 285 follow-up subjects.

cidence of self-reported vulvar pain symptoms consistent
with vulvodynia, suggesting that as many as 1 in 20 women
experience new-onset genital pain lasting at least 6 months
within a 1-year period. It is acknowledged that this figure
may be an overestimate or underestimate of incidence, as it
is influenced by the fact that (new) symptom status of 112
women in the original asymptomatic group was unknown
at follow-up because of failure to recontact them. There may
be concern that response bias influenced participation and
thus affected the incidence estimate, but we believe this effect is minimal for two reasons. First, the survey was pre-

TABLE 3.

sented to women as “a follow-up to the women’s health survey you answered approximately one year ago” without
mention that occurrence of genital pain symptoms would be
assessed. This reduced the opportunity for refusal based on
not wanting to talk about (new) symptoms. Second, nearly
two thirds of nonresponse was the result of disconnected
numbers and subjects no longer at the residence (n  88 of
n  140 nonresponders); only 28 subjects (or 6.6% of the original population) refused to participate. Thus, the majority of
nonresponse was not based on likelihood (or lack thereof) to
participate because of the nature of the survey but rather the

CHARACTERISTICS OF WOMEN WITH AND WITHOUT SELF-REPORTED
VULVODYNIA-LIKE SYMPTOMS

Characteristic
Age (mean  SD)
Overall health (mean  SD)a
Quality of life (mean  SD)b
Level of stress in life (mean  SD)b,c
Premenopausal (No., %)
Raced (No., %)
White
Black
Other

Asymptomatic
(n  196)

Symptomatic
(n  52)

53.20  15.44
2.47  0.97
7.86  1.44
5.34  2.29
90 (45.9%)0

49.87  14.26
2.44  0.98
7.94  1.36
6.35  2.16
22 (42.3%)0

169 (86.22%)
12 (6.12%)0
15 (7.65%)0

47 (90.38%)
2 (2.85%)0
3 (5.77%)0

aReported as “excellent, very good, good, fair, poor” on a scale of 1–5, where 1  excellent and 5 
poor.
bReported on a scale of 1–10, where 1 is worst possible and 10 is best possible.
cp  0.05.
dOther includes Asian, Native American/Alaskan, Native Hawaiian/Pacific Islander, multiracial,
and self-described other.
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TABLE 4.

TRIGGERS

VULVODYNIA-LIKE SYMPTOMS IN WOMEN
SELF-REPORTED CHRONIC VULVAR PAIN

OF

AND WITHOUT

Asymptomatic
(n  195)a
No. (%)

Situational pain
Tampon insertion
Speculum insertion
Intercourse
Exercise

1289

3
6
7
0

WITH

Symptomatic
(n  52)
No. (%)

(1.5%)
(3.1%)
(3.6%)
(0.0%)

14
14
27
7

(26.9%)
(26.9%)
(51.9%)
(13.7%)c

Odds ratio
(95% CI)
23.6
11.6
29.0
61.9

(6.46, 85.6)b
(4.19, 32.1)b
(11.44, 73.5)b
(3.69, 1175.3)b,d

n
a1 control reported “don’t know” to all questions.
bp  0.05.
cn  1 reported “don’t know.”
dCorrection factor of 0.5 used for asymptomatic cell.

inability to make contact with a viable number. Demographic
differences between the groups further support this argument. Specifically, nonresponders were younger and more
likely to be single or divorced/separated, with a higher proportion of responders better educated and retired. These
characteristics are consistent with mobility among nonresponders and stability among responders with regard to living/employment situations and thus may explain the high
percentage of nonviable numbers. Should younger age be
positively correlated with vulvodynia, this would make our
calculation an underestimate of incidence. Conversely, if
none of the original 112 controls we failed to recontact ex-

TABLE 5.

perienced new symptoms, the most conservative estimate of
incidence would be 3.1%.
Although a number of vulvodynia studies require a minimum 3-month duration of symptoms for case definition,4,7,9,12,13 there is inconsistent evidence for using this time
frame for diagnostic purposes.14 As our study relied on selfreported symptoms without a clinical confirmation of diagnosis, we chose a longer, more conservative time frame to
reduce the possibility of misclassification by subjects confusing vulvodynia-like symptoms with other conditions that
might mimic vulvodynia but that resolve in a shorter time.
However, this stricter case definition criterion may have an

CHARACTERISTICS OF TAMPON USE IN WOMEN WITH
SELF-REPORTED VULVODYNIA-LIKE SYMPTOMS

AND WITHOUT

Method of protection
Pads/sanitary napkins only
Tampons only
Both pads/sanitary napkins
and tampons
Primary reason for not using
tampons
Unhygienic
Feel uncomfortable
Pain with insertion
Never tried tampons
Other
First tampon experience
Neither painful nor uncomfortable
Uncomfortable but not painful
Painful the first time only
So painful that never tried
tampons again
Either painful or uncomfortableg

Asymptomatic
No. (%)

Symptomatic
No. (%)

(95% CI)

(n  196)
69 (35.2%)
49 (25%) 2
78 (39.8%)

(n  52)
13 (25%) 2
7 (13.5%)
32 (61.5%)

0.61 (0.31, 1.23)
0.47 (0.20, 1.10)
2.42 (1.29, 4.53)a

(n  68)b

(n  13)

3 (4.4%)
21 (30.9%)
5 (7.4%)
15 (22.1%)
24 (35.3%)
(n  166)c
60 (35.7%)
78 (46.4%)
20 (11.9%)
8 (4.8%)

2 (15.4%)
6 (46.2%)
0 (0.0%)
2 (15.4%)
3 (23.1%)
(n  48)d
10 (20.4%)
29 (59.2%)
6 (12.2%)
3 (6.1%)

3.94 (0.59, 26.3)
1.92 (0.57, 6.41)
––
0.64 (0.13, 3.22)
0.55 (0.14, 2.19)

38 (79.17%)

106 (63.86%)

2.15 (1.0, 4.62)g

1.0e
2.23 (1.0, 4.93)f
1.8 (0.58, 5.58)
2.25 (0.51, 9.95)

 0.005.
 1 refused to answer.
cn  28 never tried tampons, and 2 reported “don’t know.”
dn  3 never tried tampons, and 1 reported “don’t know.”
eServed as the referent group for odds ratio calculations.
fp  0.044.
gCalculated by combining “uncomfortable but not painful, painful the first time only, and so painful
never tried again”; marginally significant at p  0.046.
ap

bn
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impact on the incidence measurement. Specifically, it is possible that some of the original controls experienced vulvodynia-like symptoms within the time between studies, but
because of the relatively short follow-up period, these symptoms were present for less than 6 months. Thus, a longer follow-up time (e.g., 2 years, 5 years, or 10 years) may better
capture new-onset chronic symptoms of such a long duration. The goal of this study was short term, however, and
aimed to examine how many women experienced new
symptoms within a year, which is the standard amount of
time between well-care gynecological or physical examinations.
Interestingly, the stricter symptom duration criterion
adopted in this study may also explain why, at follow-up, 7
original controls unexpectedly reported vulvodynia-like
symptoms occurring prior to the original survey. Initially, it
seems that these women should have answered “yes” to the
vulvodynia symptom question on the initial survey and consequently have been considered as original cases. However,
they may have begun to experience symptoms in the months
leading up to the original survey but not met the 6-month
definition until after the original survey passed. Consequently, they would not have been characterized as cases
originally but would also have been missed in an incidence
calculation, as symptom onset occurred prior to the first survey and not during the period of interest, which was the time
between surveys. Had they been characterized as cases in
this situation, the incidence in this study would have been
7.9%.
Of note, there was a subset of original cases (n  36) who
reported vulvodynia-like symptoms at first contact but subsequently denied lower genital tract pain at follow-up, a
finding that was not expected, as the case definition question assessed “ever” as opposed to “currently” experiencing
vulvodynia-like symptoms. Because the survey did not include additional questions to probe for potential contradictions in case answers, these women were removed from the
follow-up analysis because they could be confirmed as neither cases nor controls. We suggest several possible explanations for this discrepancy in case reporting between original and follow-up surveys. First, if subjects experienced a
resolution of symptoms, either spontaneously or secondary
to a medical intervention since the first telephone contact,
they may have misunderstood the question as assessing current symptoms and thus answered negatively. This hypothesis, in combination with the fact that approximately one
third of original cases reported no symptoms within the past
year, would be consistent with previous studies showing that
a subset of women will not report vulvar pain for more than
1 year.3,7,9,15
A prospective study by Peckham et al.15 followed 67
women with vulvar pain for 15 years and found that approximately 50% of subjects had spontaneous resolution of
their pain, with most remissions occurring within 6 months
of pain onset. Pharmacological or behavioral treatment can
also have a substantial impact on reduction of symptoms,16–18 with a recent study demonstrating complete
symptom resolution in 40% of patients treated with combination antidepressent therapy for 6 months.19 Even if
symptoms had resolved, however, original cases still should
have answered “yes” to the vulvodynia screening question,
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as it queried for lifetime history of symptoms. Alternately,
these cases may have denied symptoms because of embarrassment or discomfort as a result of the possibility of being
overheard by others in close proximity during the time of
the survey. Follow-up questions to probe such a discrepancy
should be considered in similar studies in the future. Nonetheless, our data suggest that vulvodynia-like symptoms
may resolve in a subset of women, which highlights the need
for placebo-controlled trials when evaluating vulvar pain interventions. Studies examining resolution of symptoms in diagnosed women would lend insight into possible treatments
and a better understanding of the natural course of disease
in afflicted women.
Consistent with other studies, we found vulvodynia-like
symptoms to be significantly related to the following situations: speculum insertion, intercourse, exercise, and tampon
use, especially first-time tampon use.4,6–9,20,21 Ten of the 14
symptomatic women who reported pain with tampon insertion also reported pain with speculum insertion, demonstrating that there is variation in symptoms even within the
commonality of insertional pain. Taken together, these characteristics may serve to support the symptomatic population
as having a symptom history reflective of women diagnosed
with vulvodynia14 and to underscore the varied presentations of the disease. It is well documented that vulvodynia
has a significant negative effect on sexual functioning,22 with
dyspareunia in particular as a common complaint of diagnosed women.14 Thus, it is not surprising that intercourse
was the most notable situation in which symptomatic
women in our study experienced pain, with double the number of women suffering dyspareunia than pain in other insertional circumstances. It is important to remember, however, that dyspareunia alone is not sufficient for diagnosis
of vulvodynia, as it may result from a myriad of conditions,
including vaginismus, interstitial cystitis, endometriosis, and
vaginal atrophy.23
Our original study with this national sample of women
found that women with vulvodynia-like symptoms had a
2.14 significantly increased odds of having ever used tampons regularly compared with their asymptomatic counterparts.6 The temporal relationship between ever using tampons and symptom onset was not assessed at that time,
however. In considering the pathogenesis of disease, it has
been suggested that inflammatory pathways and neuropathies are involved in the development of vulvodynia.14
Other studies have considered the impact of early life effects
that introduce vestibular trauma (e.g., childhood abuse) on
the subsequent development of vulvodynia, with inconsistent results.12,24,25 Thus, one hypothesis that stemmed from
the initial survey study was that in certain women, early regular tampon use was traumatic in that it damaged vestibular nerves or instigated inflammatory processes that later
manifested as vulvodynia. Although gaining information to
support this hypothesis is not possible from a survey alone,
this follow-up study served as an opportunity to further explore the association between experiences with tampons and
vulvodynia-like symptoms.
When asked about current preferred methods of menstrual protection, symptomatic women were not only less
likely to use only tampons but also less likely to use only
sanitary napkins; rather they were nearly 2.5 times as likely
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to prefer a combination of tampons and napkins. This may
suggest that the “ever used tampons regularly” findings
characterized in the initial survey occurred prior to symptom onset and that once women experienced chronic genital pain, tampons triggered or exacerbated symptomatic periods enough to encourage avoidance of solely using
tampons. Supporting this, symptomatic women were more
likely than their asymptomatic counterparts to not use tampons because of physical discomfort, although associations
were not significant. Similarly, the chafing some women experience with sanitary napkins may also trigger or exacerbate symptoms and result in avoidance of this method of
protection. Thus, the preference symptomatic women exhibited for a combination method of protection may reflect
differences in symptomatology (e.g., pain with insertion vs.
pressure or constant vs. intermittent pain) or timing of symptoms in relation to the menstrual cycle. It is difficult to assess the extent of such associations because of the small sample size.
When considering initial tampon experiences, women
who reported symptoms consistent with vulvodynia were
2.15 times as likely to have experienced discomfort or pain
with first tampon use. This association is substantially lower
than the 7–8-fold risk reported most recently by Harlow and
Stewart7 but more consistent with the 2.4 increase in risk reported in an earlier study by this same group.4 Even though
this experience was not severe enough to significantly prevent women from ever trying tampons again, the extent of
pain or discomfort with first-time tampon insertion should
be examined as an early indicator of vulvodynia and, thus,
as a possible screening mechanism for early-stage disease.
The follow-up of this national sample of women indicates
that the annual occurrence of new-onset chronic genital pain
may be substantial. Although our study does not confirm
vulvodynia in any of the symptomatic patients, it has been
demonstrated that self-reported symptom history is a reliable means of assessing vulvodynia, with office examination
confirming disease in 96% of those who self-reported symptoms on a survey.13 This reliability of self-reporting, combined with our finding that nearly 5% of previously asymptomatic women indicated new vulvodynia-like symptoms
within a 12-month period, should serve to encourage the importance of healthcare providers’ sensitivity to asking patients about (new-onset) chronic genital pain at annual examinations.
It is important to raise awareness about the condition and
for the clinical community to be proactive in asking patients
about chronic genital pain at routine annual examinations.
Although sample size limited the interpretation of tampon
findings, preliminary data suggest that the issues of firsttime tampon experiences and the way in which symptomatic
women handle their menstrual cycle are complex, making it
difficult to discern specific questions to assist with the diagnosis of vulvodynia. To truly understand how such measurements relate to the incidence of vulvodynia, future largescale studies are needed in which physical examination or
medical record review is done to confirm whether self-reported chronic vulvar pain symptoms are consistent with a
diagnosis of vulvodynia and to explore the issues raised here
about symptom resolution and tampon use in a diagnosed
population of women.
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